| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Gabriela L Martins, Cláudia N Ferreira, András Palotás, Natália P Rocha, Helton J Rei. Role of oxysterols in the activation of the NLRP3 inflammasome as a potential pharmacological approach in Alzheimer's. Current neuropharmacology. 2022-03-27. PMID:35339182. |
as dyslipidemia is a risk factor for dementia, and cholesterol can also activate the inflammasome, a possible link between lipid levels and the nlrp3 inflammasome has been proposed in alzheimer's. |
2022-03-27 |
2023-08-13 |
Not clear |
| Mattia Spano, Giacomo Di Matteo, Cinzia Ingallina, Donatella Ambroselli, Simone Carradori, Marialucia Gallorini, Anna Maria Giusti, Andrea Salvo, Michela Grosso, Luisa Mannin. Modulatory Properties of Food and Nutraceutical Components Targeting NLRP3 Inflammasome Activation. Nutrients. vol 14. issue 3. 2022-03-12. PMID:35276849. |
nlrp3 inflammasome represents one of the main protein complexes involved in the development of inflammatory events, and its activity has been largely demonstrated to be connected with inflammatory or autoinflammatory disorders, including diabetes, gouty arthritis, liver fibrosis, alzheimer's disease, respiratory syndromes, atherosclerosis, and cancer initiation. |
2022-03-12 |
2023-08-13 |
Not clear |
| Tao Liang, Yang Zhang, Suyuan Wu, Qingjie Chen, Lin Wan. The Role of NLRP3 Inflammasome in Alzheimer's Disease and Potential Therapeutic Targets. Frontiers in pharmacology. vol 13. 2022-03-07. PMID:35250595. |
the role of nlrp3 inflammasome in alzheimer's disease and potential therapeutic targets. |
2022-03-07 |
2023-08-13 |
Not clear |
| Kai-Po Chen, Kuo-Feng Hua, Fu-Ting Tsai, Ting-Yu Lin, Chih-Yuan Cheng, Ding-I Yang, Hsien-Ta Hsu, Tz-Chuen J. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease. Journal of neuroinflammation. vol 19. issue 1. 2022-02-27. PMID:35219323. |
mcc950 is a highly selective and potent small-molecule inhibitor of nlrp3 that has been used for the treatment of several diseases such as alzheimer's disease. |
2022-02-27 |
2023-08-13 |
mouse |
| Muhammad Haseeb, Nasir Javaid, Farzana Yasmeen, Uisuk Jeong, Ji Hye Han, Juhwan Yoon, Jee Yeon Seo, Jae Kyung Heo, Ho Chul Shin, Moon Suk Kim, Wook Kim, Sangdun Cho. Novel Small-Molecule Inhibitor of NLRP3 Inflammasome Reverses Cognitive Impairment in an Alzheimer's Disease Model. ACS chemical neuroscience. 2022-02-24. PMID:35196855. |
novel small-molecule inhibitor of nlrp3 inflammasome reverses cognitive impairment in an alzheimer's disease model. |
2022-02-24 |
2023-08-13 |
mouse |
| Muhammad Haseeb, Nasir Javaid, Farzana Yasmeen, Uisuk Jeong, Ji Hye Han, Juhwan Yoon, Jee Yeon Seo, Jae Kyung Heo, Ho Chul Shin, Moon Suk Kim, Wook Kim, Sangdun Cho. Novel Small-Molecule Inhibitor of NLRP3 Inflammasome Reverses Cognitive Impairment in an Alzheimer's Disease Model. ACS chemical neuroscience. 2022-02-24. PMID:35196855. |
aberrant activation of the nod-like receptor family pyrin domain-containing 3 (nlrp3) inflammasome plays an essential role in multiple diseases, including alzheimer's disease (ad) and psoriasis. |
2022-02-24 |
2023-08-13 |
mouse |
| Jonathan Hulse, Kiran Bhaska. Crosstalk Between the NLRP3 Inflammasome/ASC Speck and Amyloid Protein Aggregates Drives Disease Progression in Alzheimer's and Parkinson's Disease. Frontiers in molecular neuroscience. vol 15. 2022-02-21. PMID:35185469. |
crosstalk between the nlrp3 inflammasome/asc speck and amyloid protein aggregates drives disease progression in alzheimer's and parkinson's disease. |
2022-02-21 |
2023-08-13 |
Not clear |
| Ilie Cosmin Stancu, Chritica Lodder, Pablo Botella Lucena, Sarah Vanherle, Manuel Gutiérrez de Ravé, Dick Terwel, Astrid Bottelbergs, Ilse Dewachte. The NLRP3 inflammasome modulates tau pathology and neurodegeneration in a tauopathy model. Glia. 2022-02-17. PMID:35174546. |
an active role of neuroinflammation and the nlrp3 inflammasome in alzheimer's disease and related tauopathies is increasingly identified, supporting nlrp3 as an interesting therapeutic target. |
2022-02-17 |
2023-08-13 |
mouse |
| Soroush Moasses Ghafary, Paula M Soriano-Teruel, Shima Lotfollahzadeh, Mónica Sancho, Eva Serrano-Candelas, Fatemeh Karami, Stephen J Barigye, Iván Fernández-Pérez, Rafael Gozalbes, Maryam Nikkhah, Mar Orzáez, Saman Hosseinkhan. Identification of NLRP3 International journal of molecular sciences. vol 23. issue 3. 2022-02-15. PMID:35163573. |
the dysregulation of the best-characterized complex, the nlrp3 inflammasome, has been linked to the pathogenesis of diseases such as multiple sclerosis, type 2 diabetes mellitus, alzheimer's disease, and cancer. |
2022-02-15 |
2023-08-13 |
Not clear |
| Changwen Zhang, Ayyiliath M Sajith, Xiaotian Xu, Jianxiong Jiang, J Phillip Bowen, Amol Kulkarni, Jiukuan Ha. Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation. Bioorganic & medicinal chemistry. vol 58. 2022-02-12. PMID:35151118. |
dysregulation of nlrp3 signaling results in microglial activation and triggers inflammatory responses contributing to the development of neurological disorders including ischemic stroke, schizophrenia, alzheimer's disease (ad), parkinson's disease (pd), and amyotrophic lateral sclerosis (als). |
2022-02-12 |
2023-08-13 |
mouse |
| Yawen Cai, Yuhui Chai, Yu Fu, Yingdi Wang, Yiming Zhang, Xue Zhang, Lingpeng Zhu, Mingxing Miao, Tianhua Ya. Salidroside Ameliorates Alzheimer's Disease by Targeting NLRP3 Inflammasome-Mediated Pyroptosis. Frontiers in aging neuroscience. vol 13. 2022-02-07. PMID:35126093. |
salidroside ameliorates alzheimer's disease by targeting nlrp3 inflammasome-mediated pyroptosis. |
2022-02-07 |
2023-08-13 |
Not clear |
| Yawen Cai, Yuhui Chai, Yu Fu, Yingdi Wang, Yiming Zhang, Xue Zhang, Lingpeng Zhu, Mingxing Miao, Tianhua Ya. Salidroside Ameliorates Alzheimer's Disease by Targeting NLRP3 Inflammasome-Mediated Pyroptosis. Frontiers in aging neuroscience. vol 13. 2022-02-07. PMID:35126093. |
amyloid β-protein (aβ) is reported to activate nlrp3 inflammasomes and drive pyroptosis, which is subsequently involved in the pathogenesis of neurodegenerative diseases, such as alzheimer's disease (ad). |
2022-02-07 |
2023-08-13 |
Not clear |
| Saba Bakhshi, Saeedeh Shams. MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes. International immunopharmacology. vol 106. 2022-02-06. PMID:35124417. |
the nlrp3 could be involved in the pathogenesis of several inflammatory and autoimmune diseases such as type 2 diabetes mellitus, multiple sclerosis (ms), atherosclerosis, alzheimer's disease (ad), cryopyrin-associated periodic syndrome (caps), and infectious diseases. |
2022-02-06 |
2023-08-13 |
Not clear |
| Takumi Satoh, Dorit Trudler, Chang-Ki Oh, Stuart A Lipto. Potential Therapeutic Use of the Rosemary Diterpene Carnosic Acid for Alzheimer's Disease, Parkinson's Disease, and Long-COVID through NRF2 Activation to Counteract the NLRP3 Inflammasome. Antioxidants (Basel, Switzerland). vol 11. issue 1. 2022-01-21. PMID:35052628. |
potential therapeutic use of the rosemary diterpene carnosic acid for alzheimer's disease, parkinson's disease, and long-covid through nrf2 activation to counteract the nlrp3 inflammasome. |
2022-01-21 |
2023-08-13 |
Not clear |
| Li Shao, Chen Dong, Deqin Geng, Qing He, Yu Sh. Ginkgolide B inactivates the NLRP3 inflammasome by promoting autophagic degradation to improve learning and memory impairment in Alzheimer's disease. Metabolic brain disease. 2022-01-20. PMID:35050445. |
ginkgolide b inactivates the nlrp3 inflammasome by promoting autophagic degradation to improve learning and memory impairment in alzheimer's disease. |
2022-01-20 |
2023-08-13 |
mouse |
| Li Shao, Chen Dong, Deqin Geng, Qing He, Yu Sh. Ginkgolide B inactivates the NLRP3 inflammasome by promoting autophagic degradation to improve learning and memory impairment in Alzheimer's disease. Metabolic brain disease. 2022-01-20. PMID:35050445. |
the nlr family, pyrin domain containing 3 (nlrp3) inflammasome drives the progression of alzheimer's disease (ad). |
2022-01-20 |
2023-08-13 |
mouse |
| Chenyang Ha. Corrigendum to "New mechanism of neuroinflflammation in Alzheimer's disease: The activation of NLRP3 inflflammasome mediated by gut microbiota" [Progress in Neuropsychopharmacology & Biological Psychiatry 100 (2020) 109884]. Progress in neuro-psychopharmacology & biological psychiatry. vol 114. 2021-12-09. PMID:34838637. |
corrigendum to "new mechanism of neuroinflflammation in alzheimer's disease: the activation of nlrp3 inflflammasome mediated by gut microbiota" [progress in neuropsychopharmacology & biological psychiatry 100 (2020) 109884]. |
2021-12-09 |
2023-08-13 |
Not clear |
| Francesca La Rosa, Roberta Mancuso, Simone Agostini, Federica Piancone, Ivana Marventano, Marina Saresella, Ambra Hernis, Chiara Fenoglio, Daniela Galimberti, Elio Scarpini, Mario Cleric. Pharmacological and Epigenetic Regulators of NLRP3 Inflammasome Activation in Alzheimer's Disease. Pharmaceuticals (Basel, Switzerland). vol 14. issue 11. 2021-11-30. PMID:34832969. |
pharmacological and epigenetic regulators of nlrp3 inflammasome activation in alzheimer's disease. |
2021-11-30 |
2023-08-13 |
human |
| Kishore Aravind Ravichandran, Michael T Henek. Inflammasome activation in neurodegenerative diseases. Essays in biochemistry. 2021-11-30. PMID:34846519. |
furthermore, we discuss the key factors that contribute to nlrp3 inflammasome activation in the different neuroinflammatory diseases, like alzheimer's disease (ad), parkinson's disease (pd), and amyotrophic lateral sclerosis (als). |
2021-11-30 |
2023-08-13 |
mouse |
| Hao Tang, Michael Hart. Investigating Markers of the NLRP3 Inflammasome Pathway in Alzheimer's Disease: A Human Post-Mortem Study. Genes. vol 12. issue 11. 2021-11-29. PMID:34828359. |
investigating markers of the nlrp3 inflammasome pathway in alzheimer's disease: a human post-mortem study. |
2021-11-29 |
2023-08-13 |
human |